Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
Asset disposition
Director departure
Quarterly results
Auditor change
Acq. announced
Consulting agrmnt
Appointed director
Inv. presentation
LISATA THERAPEUTICS, INC. (CLBS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update",
"2 0 2 3 L"
07/13/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
07/11/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors"
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update",
"2 0 2 3 L"
05/01/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
02/06/2023 8-K Quarterly results
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
10/17/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
10/14/2022 8-K/A Financial Statements and Exhibits  Interactive Data
Docs: "Consent of Withum Smith+Brown, PC, independent registered public accounting firm"
10/04/2022 8-K/A Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "“Cend Business” section excerpt from Registration Statement",
"“Risk Factors” section excerpt from Registration Statement",
"Unaudited condensed interim financial statements of Cend as of June 30, 2022 and for the six months ended June 30, 2022 and 2021",
"Unaudited pro forma condensed combined financial information of the Company as of June 30, 2022 and for the six months ended June 30, 2022"
09/29/2022 8-K Quarterly results
09/26/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
09/22/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "NOVEL INTRATUMORAL DELIVERY TECHNOLOGY TO IMPROVE THERAPEUTIC EFFICACY OF"
09/15/2022 8-K Appointed a new director
Docs: "Certificate of Amendment (Reverse Stock Split) to the Amended and Restated Certificate of Incorporation",
"Certificate of Amendment (Name Change) to the Amended and Restated Certificate of Incorporation",
"WITNESSETH:",
"INDEMNIFICATION AGREEMENT",
"BASKING RIDGE, NJ and SAN DIEGO, CA",
"Lisata Therapeutics, Inc. Corporate Presentation, September 15, 2022"
09/14/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CALADRIUS BIOSCIENCES, INC.",
"Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics All Merger-related proposals approved at the Annual Meeting of Stockholders"
09/02/2022 425 Form 425 - Prospectuses and communications, business combinations:
08/19/2022 8-K Quarterly results
08/15/2022 425 Form 425 - Prospectuses and communications, business combinations:
08/10/2022 425 Form 425 - Prospectuses and communications, business combinations:
08/05/2022 8-K Quarterly results
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
07/29/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
07/29/2022 EFFECT Form EFFECT - Notice of Effectiveness:
07/26/2022 S-4/A Form S-4/A - Registration of securities, business combinations: [Amend]
07/06/2022 425 Form 425 - Prospectuses and communications, business combinations:
06/15/2022 S-4 Form S-4 - Registration of securities, business combinations:
06/09/2022 425 Form 425 - Prospectuses and communications, business combinations:
05/23/2022 8-K Quarterly results
05/05/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/05/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy